Minnesota is currently home to 2107 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Minneapolis, Rochester, Saint Paul and Duluth. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
A Study to Evaluate the Effectiveness and Safety of Dysport® for the Prevention of Chronic Migraine in Adults
NCT06047444
Recruiting
The purpose of this study is to understand the safety and effectiveness of the study drug, Dysport® when compared with placebo in preventing chronic migraine. A migraine is a headache with severe throbbing pain or a pulsating sensation, usually on one side of the head, and is often accompanied by feeling or being sick and a sensitivity to bright lights and sound. Chronic migraine is defined as having at least 15 days of headache a month with at least 8 of those days being migraine headache day... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/29/2025
Locations: Minneapolis Clinic of Neurology, Burnsville, Minnesota
Conditions: Chronic Migraine
Register for Updates
Impact of Improving Footwear Options
NCT05601869
Recruiting
Veterans with leg amputations have limited footwear options because their artificial feet do not change shapes for different shoes. Studies have shown that women with amputations receive more frequent prosthetics care than men, but are less satisfied with the fit, comfort, and appearance of their prostheses. The investigators' previous research indicates that women Veterans would like to be able to wear a broader variety of footwear, and those who perceive more footwear limitations tend to have... Read More
Gender:
ALL
Ages:
Between 18 years and 89 years
Trial Updated:
07/29/2025
Locations: Minneapolis VA Health Care System, Minneapolis, MN, Minneapolis, Minnesota
Conditions: Amputation
Register for Updates
Efineptakin Alfa and Pembrolizumab for the Treatment of Recurrent Glioblastoma
NCT05465954
Recruiting
This phase II trial tests the safety and side effects of efineptakin alfa and pembrolizumab in treating patients with glioblastoma that has come back (recurrent). Efineptakin alfa is an immunotherapy drug that works by helping the immune system fight tumor cells. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving efineptakin alfa and pembrolizumab may ki... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/29/2025
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: High Grade Astrocytic Tumor, Recurrent Glioblastoma, IDH-Wildtype, Recurrent Gliosarcoma
Register for Updates
Safety and Tolerability of Pirfenidone in Acute Pancreatitis
NCT05350371
Recruiting
The goal of the current pilot clinical trial is to evaluate the safety and tolerability of pirfenidone in patients with predicted moderately severe and severe acute pancreatitis. Pirfenidone is currently approved by FDA for the treatment of idiopathic pulmonary fibrosis. Now, over 5 years of data has accumulated demonstrating safety of its use in humans. The investigators' preclinical data suggest that pirfenidone is very effective in reducing the severity of acute pancreatitis in animal models.... Read More
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
07/29/2025
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Pancreatitis, Acute
Register for Updates
Evolut™ EXPAND TAVR II Pivotal Trial
NCT05149755
Recruiting
Obtain safety and effectiveness data to support indication expansion for the Medtronic TAVR System to include patients with moderate, AS.
Gender:
ALL
Ages:
65 years and above
Trial Updated:
07/29/2025
Locations: Abbott Northwestern Hospital, Minneapolis, Minnesota
Conditions: Moderate Aortic Valve Stenosis
Register for Updates
First in Human Study of TORL-1-23 in Participants With Advanced Cancer
NCT05103683
Recruiting
This first-in-human study will evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of TORL-1-23 in patients with advanced cancer
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/29/2025
Locations: University of Minnesota, Minneapolis, Minnesota
Conditions: Advanced Solid Tumor, Ovarian Cancer, Endometrial Cancer, NSCLC
Register for Updates
Study of ONCOFID-P-B (PACLITAXEL-HYALURONIC ACID)
NCT05024773
Recruiting
This is a phase III, single-arm, multicenter, international study to assess the efficacy and safety of ONCOFID-P-B following intravesical instillation in adult patients with histologically and cytologically confirmed CIS, with or without concomitant Ta-T1, who are unresponsive to BCG therapy and unwilling or unfit to undergo radical cystectomy. After providing written informed consent (in presence of an Independent Witness, if applicable), patients will receive an induction therapy consisting o... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/29/2025
Locations: University of Minnesota, Minneapolis, Minnesota
Conditions: Bladder Carcinoma in Situ (CIS)
Register for Updates
Chemotherapy With or Without Immunotherapy for Peritoneal Mesothelioma
NCT05001880
Recruiting
This phase II trial compares the usual treatment alone (carboplatin, pemetrexed, and bevacizumab) to using immunotherapy (atezolizumab) plus the usual treatment in treating patients with peritoneal mesothelioma. The usual treatment consists of surgery or chemotherapy. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slow... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/29/2025
Locations: Sanford Joe Lueken Cancer Center, Bemidji, Minnesota
Conditions: Peritoneal Malignant Mesothelioma
Register for Updates
Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate Cancer
NCT04787744
Recruiting
This is a prospective, open-label, multi-center seamless phase II to phase III randomized clinical trial designed to compare SST with or without PET-directed local therapy in improving the castration-resistant prostate cancer-free survival (CRPC-free survival) for Veterans with oligometastatic prostate cancer. Oligometastasis will be defined as 1-10 sites of metastatic disease based on the clinical determination of the LSI which incorporates all imaging, clinical, and pathologic data available.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
07/29/2025
Locations: Minneapolis VA Health Care System, Minneapolis, MN, Minneapolis, Minnesota
Conditions: Prostate Cancer, Oligometastasis, Oligorecurrence, Recurrent Prostate Cancer, Metastatic Prostate Cancer, De Novo Prostate Cancer
Register for Updates
Novel SEQUEnced Immunotherapy With Anti-angiogenesis and Chemotherapy in Advanced gastroesophageaL Adenocarcinoma
NCT04069273
Recruiting
Cohort 1 \[CLOSED\] Study treatment involves two segments: (1) Induction Immunotherapy segment with pembrolizumab monotherapy every 3 weeks until irRECIST PD and (2) Combination Therapy segment. Nab-paclitaxel may be utilized in place of paclitaxel at investigator's discretion for subjects with paclitaxel reactions. Cohort 2 Patients are randomized to Arm A or B. Treatment in both arms includes pembrolizumab + RAM + paclitaxel.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/29/2025
Locations: Mayo Clinic- Minnesota, Rochester, Minnesota
Conditions: Gastric Cancer, GastroEsophageal Cancer, Adenocarcinoma
Register for Updates
Alpha/Beta TCD HCT in Patients With Inherited BMF Disorders
NCT03579875
Recruiting
This is a phase II trial of T cell receptor alpha/beta depletion (α/β TCD) peripheral blood stem cell (PBSC) transplantation in patients with inherited bone marrow failure (BMF) disorders to eliminate the need for routine graft-versus-host disease (GVHD) immune suppression leading to earlier immune recovery and potentially a reduction in the risk of severe infections after transplantation.
Gender:
ALL
Ages:
65 years and below
Trial Updated:
07/29/2025
Locations: Masonic Cancer Center at University of Minnesota, Minneapolis, Minnesota
Conditions: Fanconi Anemia, Severe Aplastic Anemia, Myelodysplastic Syndromes, T Cell Receptor Alpha/Beta Depletion, Telomere Biology Disorder, Bone Marrow Failure, Dyskeratosis Congenita, Telomere Biology Disorders
Register for Updates
Product Performance Report: Evaluate Long-term Reliability & Performance of Medtronic Marketed Cardiac Therapy Products
NCT00271180
Recruiting
The main purpose of the Product Performance Report (formerly referred to as System Longevity Study) is to evaluate long-term performance of Medtronic market-released cardiac rhythm products by analyzing product survival probabilities.
Gender:
ALL
Ages:
All
Trial Updated:
07/29/2025
Locations: Not set, Coon Rapids, Minnesota
Conditions: Arrhythmia, Bradycardia, Heart Failure, Sinus Tachycardia
Register for Updates